Mapping the complement-targeted landscape in igA nephropathy: a systematic review with structured descriptive synthesis. (PubMed, Front Med (Lausanne)) - Oct 18, 2026 - "Phase II trials of ravulizumab, iptacopan, and cemdisiran provided early efficacy signals with no encapsulated-bacterial events reported, though small size and short follow-up limit safety inference. These observations are hypothesis-generating and underscore the need for mechanism-specific phase III programmes with hard renal endpoints and individual patient-level meta-analyses to advance precision complement therapeutics in IgAN. https://www.crd.york.ac.uk/PROSPERO/view/CRD420261385690."
Journal • Review • Fibrosis • Glomerulonephritis • IgA Nephropathy • Immunology • Infectious Disease • Pneumococcal Infections • Renal Disease
|
|
Chang-Ying Zhong; Li-Nan Zhang; Xin-Yu Li; Yang Liu
|